TAK 935

Drug Profile

TAK 935

Alternative Names: OV-935; TAK-935

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Ovid Therapeutics; Takeda
  • Class Antiepileptic drugs; Heterocyclic compounds; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Cholesterol 24-hydroxylase inhibitors; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Tuberous sclerosis

Most Recent Events

  • 18 Jul 2018 Takeda Pharmaceutical and Ovid Therapeutics plans an open-label, long-term extension ENDYMION trial for developmental and epileptic encephalopathies in 3Q 2018
  • 18 Jul 2018 Takeda Pharmaceuticals and Ovid Therapeutics plans the phase II ARCADE and ELEKTRA trials in Early infantile epileptic encephalopathy 2 and Duplication 15q syndrome (In children, In adolescents) and Dravet syndrome or Lennox-Gastaut syndrome (In children, In adolescents), respectively, in 3Q 2018 (700297816; 700295744)
  • 21 Apr 2018 Pharmacodynamics data from studies in Epilepsy presented at the 70th Annual Meeting of the American Academy of Neurology (AAN-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top